Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPH
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
Korea has newly adopted 8mg Silodosin once daily. Against these backdrops, this clinical
study is designed to demonstrate that the newly adopted dose is not inferior to the existing
dose in its efficacy and safety.